

microRNA signatures of perioperative myocardial injury after elective non-cardiac surgery: prospective observational cohort study.

Shaun M. May¹, Tom E.F. Abbott¹, Ana Gutierrez Del Arroyo¹, Anna Reyes², Gladys Martir², Robert C.M. Stephens², David Brealey², Brian H. Cuthbertson^{3,4}, Duminda N. Wijeyesundera³, Rupert M. Pearse,¹ Gareth L. Ackland¹

1. Translational Medicine & Therapeutics, William Harvey Research Institute, Queen Mary University of London, EC1M 6BQ
2. University College London NHS Hospitals Trust, London, UK
3. Department of Anaesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada
4. Department of Critical Care Medicine, Sunnybrook Health Science Centre, Toronto, Ontario, Canada.

Running title: MicroRNA and perioperative myocardial injury.

Correspondence to: G L Ackland, Reader, Translational Medicine & Therapeutics, William Harvey Research Institute, Queen Mary University of London, EC1M 6BQ. United Kingdom; g.ackland@qmul.ac.uk +44 208 882 2100

MESH Keywords: MicroRNA; Perioperative Period; Postoperative Complications; perioperative myocardial injury; non-cardiac surgery;

Background: Elevated plasma/serum troponin, indicating perioperative myocardial injury (PMI), is common after non-cardiac surgery. However, underlying mechanisms remain unclear. Acute coronary syndrome (ACS) is associated with the early appearance of circulating microRNAs, which regulate post-translational gene expression. We hypothesised that if PMI and ACS share pathophysiological mechanisms, common microRNA signatures should be evident.

Methods: Nested case-control study of samples obtained before and after non-cardiac surgery from patients enrolled in two prospective observational studies of PMI (postoperative troponin I/T > 99th centile). In cohort one, serum microRNAs were compared between patients with/without PMI, matched for age, gender and comorbidity. Real-time polymerase chain reaction quantified relative microRNA expression (cycle quantification threshold < 37) before and after surgery for microRNA signatures associated with ACS, blinded to PMI. In cohort two, we analysed (EdgeR) microRNA from plasma extracellular vesicles using next-generation sequencing (Illumina HiSeq500). microRNA-messenger RNA-function pathway analysis was performed (DIANA miRPath v3.0/TopGO).

Results: MicroRNA were detectable in all 59 patients (median age: 67yrs (61-75); 42% male), who had similar clinical characteristics independent of developing PMI. In cohort one, PMI was not associated with increased serum microRNA expression levels after surgery (hsa-miR-1-3p mean fold-change (FC): 3.99 (95%CI: 1.95-8.19); hsa-miR-133-3p FC: 5.67 (95%CI: 2.94-10.91); $p < 0.001$). hsa-miR-208b-3p was more commonly detected after PMI (odds ratio (OR): 10.0 (95%CI: 1.9-52.6); $p < 0.01$). Bioinformatic analysis of differentially expressed microRNAs from cohorts one and two identified pathways associated with adrenergic stress involving calcium dysregulation, rather than ischaemia.

Conclusions: Circulating microRNAs synonymous with cardiac ischaemia were universally elevated in patients after surgery, independent of developing myocardial injury.

Introduction

Perioperative myocardial injury, as defined by elevated plasma troponin after non cardiac surgery occurs in up to $\geq 25\%$ patients¹ and precedes subsequent non-cardiac morbidity.²

Preoperative computerized tomography coronary angiogram shows that perioperative myocardial injury occurs across the spectrum of coronary artery disease, suggesting that there are likely to be several pathophysiologic mechanisms that contribute to asymptomatic elevations in troponin after surgery.³

Acute coronary syndrome (ACS) is associated with the release of microRNAs from cardiac tissue, frequently before increases in plasma troponin are detectable.⁴ MicroRNAs are small non-coding RNA molecules (approximately 23 nucleotides) that modulate gene expression through the degradation of messenger RNA and/or inhibit messenger RNA translation.⁵ MicroRNAs regulate cardiomyocyte differentiation and survival, calcium regulation, apoptosis, conduction, inflammation and necrosis.⁶ MicroRNAs also regulate intercellular communication via extracellular vesicles released from surface of the cell membrane during activation and/or exosomes, which are smaller luminal vesicles (30–100 μm in diameter) originating from intracellular endosomes.⁷ MicroRNA-1, -21, -146, -133, -208 and -499 are specifically associated with acute myocardial infarction and acute coronary syndrome in humans.^{4,8} MicroRNAs -499, -1-3 and -21 may identify patients with acute coronary syndrome even more robustly than high-sensitivity troponin.⁹ Thus, profiling circulating microRNA in patients undergoing elective non-cardiac surgery may provide genomic signatures that add mechanistic insight into perioperative myocardial injury.^{10,11}

In this study, we hypothesised that if perioperative myocardial injury and acute coronary syndrome share pathophysiological mechanisms, then microRNA profiles should be similar in both. We therefore quantified levels of expression of microRNA in samples in

serum and plasma extracellular vesicles obtained before and after non-cardiac surgery in patients who developed perioperative myocardial injury, compared to matched controls.

Methods

Study Populations

This was a nested case control study of samples obtained from UK patients enrolled in two separate studies of myocardial injury in non-cardiac surgery. Both studies were conducted in accordance with the principles of the Declaration of Helsinki and the Research Governance framework. The Measurement of exercise tolerance before surgery (METS) study was approved by the UK Medical research ethical committee (MREC: 13/LO/0135). 620 patients were recruited into the UK arm of the (METS) study cohort between 1st March 2013 and 25th March 2016.¹² The second study, approved by the UK Medical research ethical committee MREC:16/LO/06/35, recruited 189 patients at University College London Hospital from 5th October 2016 to 14th January 2019.¹³ The protocol, including original inclusion/exclusion criteria have been published but are also provided in Supplementary data.

Study 1: METS serum microRNA study

Inclusion/exclusion criteria

Inclusion criteria: Perioperative myocardial injury was defined as troponin I (TnI) >99th centile (>0.04 ng.ml⁻¹; Troponin-I Centaur CP assay, Siemens, UK). Patients with TnI>99th centile after surgery were matched with patients in whom TnI remained ≤99th centile after surgery. Samples were matched by age, sex, Revised Cardiac Risk Index Score and by day after surgery. All patients with confirmed PMI had an electrocardiogram reviewed by an independent adjudication committee We excluded patients with clinically confirmed

myocardial infarction and/or pulmonary embolus, those receiving renal replacement therapy and participants with elevated troponin-I (TnI) >99th centile before surgery (Figure 1).

METS study sample preparation

Samples were obtained once before surgery and then again on each day after surgery, until postoperative day 3. 10ml whole blood was collected in a plain tube, allowed to clot at room temperature before centrifugation (3000 rpm for 10 minutes). Serum was then aliquoted into two 2ml RNA-free tubes. The two aliquoted samples were then frozen at -70°C and subsequently used separately for troponin quantification and microRNA analysis.

METS study microRNA Isolation

Detailed methods and references are provided in Supplementary data. In brief, 200µl serum samples were screened for any obvious red discolouration (haemolysis) before isolation using the miReasy Serum/Plasma Advanced Kit (Qiagen, Denmark) in accord with manufacturer instructions. For quality control, 1µL of spike-in mixture containing UniSp2, UniSp4 and UniSp5 synthetic microRNAs (RNA Spike-in kit, Qiagen) was added to each sample (Supplementary data). 20uL RNA was isolated using RNeasy UCP MiniElute columns and stored at -20°C for subsequent batched analysis.

Circulating microRNAs.

We selected microRNA-1, 21, 146, 133, 208 and 499 as established reported microRNA signatures for ACS (Supplementary table). Meta-analysis of microRNA discovery data has highlighted these microRNAs as potential biomarkers of myocardial infarction¹⁴. The isoforms selected were chosen from the clinical studies that had isolated microRNA from

plasma/serum. The nomenclature was crosschecked using the miRBase database¹⁵

(Supplementary Material).

Quantitative RT-PCR

Detailed methods are provided in Supplementary Material. 2uL of RNA was reversed transcribed in a 10uL final reaction volume using the miRcury LNA RT kit. In accord with manufacturer recommendation, serum microRNA amounts are standardised by starting sample volume rather than RNA concentration. The reactions were performed in a Primus 96 plus thermal cycler (MWG Biotech, Ebersberg, Germany) for 60 minutes at 42°C, followed by incubation (inactivation of reaction) at 95°C for 5 min and then allowed to cool at 4°C. cDNA was then stored at -20°C. For qualitative PCR cDNA was diluted (1:40) and added to mastermix before plating on miRNA PCR custom made plates containing pre-designed miRCURY LNA miRNA PCR Assays in triplicate (Supplementary Data). Amplification was performed using the Applied Biosystem StepOneplus RT-PCR system (Applied Biosystems, California, USA). Cycle quantification (Cq) values were determined using the second derivative method (Applied Biosystem StepOneplus software, California, USA).

Quality control

Cq values were calibrated using an interplate calibrator control assay, UniSp3 pre-aliquoted on to each plate. The calibrated Cq data generated from the spike controls was used to compare each sample and identify outlier samples to be excluded from analysis. If the Cq values of the technical control produce similar values for each sample, isolation efficiency across all samples can be considered consistent. For this study, UniSp5 was used as the isolation technical control. If the Cq value was ≥ 37 , then the sample and patient was flagged as an outlier and excluded from analysis. The synthetic RNA, UniSp6 was added to the RT

reaction prior to cDNA synthesis. The outlier Cq values for UniSp6 were used to evaluate RT efficiency. Both hsa-miR-23a and hsa-miR-451 were used to detect haemolysis, which interferes with miR detection¹⁶. Samples that breached published limits of detection for haemolysis were excluded. Amplification efficiency was calculated (LinRegPCR software, Version 2017.1; Heart Failure Research Centre, Amsterdam, Netherlands)¹⁷ and individual melt curves for each PCR reaction were inspected (Supplementary data).

Cq normalisation and microRNA expression.

The Qiagen miRcury LNA miRNA Serum/Plasma Focus Panel was used to determine two reference gene(s) for this study as recommended by consensus guidelines, since there are no universal reference microRNA defined for microRNA expression studies.¹⁸ The focus panel has 179 microRNA assays commonly found in the serum and plasma. The NormFinder algorithm¹⁹ was used to determine the most suitable reference microRNA (Supplementary material). MicroRNA miR-152-3p and hsa-miR-361-5p had the lowest combined stability value (0.077) and selected as reference microRNA. Expression levels were compared using the relative Cq method, where microRNA Cq values were normalised to the geometric mean of the reference microRNA Cq values to give ΔCq values. The ΔCq values were converted to a fold change (FC) by applying the formula of $2^{-\Delta Cq}$.²⁰

Pathway analysis

We used DNA Intelligent Analysis (DIANA)-miRPath v.3.0 pathway analysis software²¹ to assess in an unbiased manner which transcriptomic processes may be altered by microRNAs (microT-CDS v5.0).

Study 2: microRNA expression levels in extracellular vesicles

Extracellular vesicles samples

To examine microRNA content in extracellular vesicles, a separate cohort of patients was recruited to prepare larger volumes of plasma which required specific different preparation to the samples obtained in METS. Plasma samples were prepared from 11 patients who underwent elective non cardiac surgery.¹³ Perioperative myocardial injury was defined as plasma high sensitivity Troponin T assay $\geq 99^{\text{th}}$ centile ($\geq 15 \text{ ng.L}^{-1}$) within 2 days of surgery (Cobas assay. Roche Diagnostics, Mannheim, Germany). 48h after surgery whole blood was collected into EDTA anticoagulant bottles, centrifuged at 3000 RPM for 10 minutes (CeprAL6 Flexicool Rota, Capricorn Laboratory Equipment, UK). The plasma layer was sterile filtered (0.8 μm membrane filter, Starlabs, Hamburg, Germany) and transferred to Eppendorf tubes. The samples were immediately stored at -80°C until batch processing. At the same time blood samples were collected, an ECG was reviewed independently to ensure no patient with myocardial infarction was included.

microRNA isolation from extracellular vesicles

Plasma samples were shipped to Exiqon (Vedbaek, Denmark) to isolate microRNA in extracellular vesicles and exosomes for next generation sequencing, masked to troponin values and clinical details. Quality control checks ensured high isolation efficiency and lack of haemolysis.¹⁶ (Supplementary Material) Library preparation was done using the NEBNext® Small RNA Library preparation kit (New England Biolabs, Massachusetts, USA). The library pool was sequenced on a NextSeq500 sequencing instrument (Illumina, San Diego, USA). Raw data was de-multiplexed and FASTQ files for each sample was generated using the bcl2fastq software (Illumina, San Diego, USA). The MicroRNA sequence reads (FASTQ) files were then mapped to Homo sapien genome (GRCh37) and the

microRNA sequence database, MiRBase V20, to generate MicroRNA sequence counts using Bowtie2 (Version 2.2.4.) software.²² MicroRNA counts were normalised for library size using Trimmed mean of M (TMM) method and differential expression of TMM analysis performed using EdgeR statistical software package.²³ Differentially expressed microRNA were used to perform Gene ontology enrichment analysis using topGO.²⁴

Statistical Analysis

Clinical characteristics of the patients were stratified according to presence, or absence, of troponin elevation >99th centile values. Categorical data are summarised as absolute values (percentage). Continuous data are presented as mean (SD), or median (IQR), unless stated otherwise. Δ Cq values were checked for normality using the Shapiro–Wilk test. For microRNA assays that were expressed in >95% across all samples, Δ Cq values were analysed using a multi-level (mixed error-component) model. The levels examined were; presence/absence of perioperative myocardial injury (>99th centile) and sampling time (before, or after, surgery).

Individual comparisons between groups were calculated using post-hoc Bonferroni tests. For microRNA expressed in <95% samples, McNemar Chi-square analysis was performed. $P < 0.05$ was considered statistically significant. All statistical analyses were undertaken using NCSS 12 (Kaysville, UT, USA). Data have been deposited in NCBI's Gene Expression Omnibus²⁵ and are accessible through GEO Series accession number GSE144777.

Sample Size Calculation.

Receiver operating character curve analysis has demonstrated that miR-499, miR-1-3 and miR-21 can be used to identify patients with acute coronary syndrome, area under the curve

(AUC) = 0.89.⁹ If these microRNA were present and/or elevated in patients at the time of detecting perioperative myocardial injury, >11 patients would be required to detect a difference in relative expression serum microRNA after surgery ($\alpha=0.01$; $1-\beta=0.9$). The sample size calculation was performed using the pROC package (R software, v3.4.3).²⁶

Results

Cohort 1: METS serum microRNA study

Patient characteristics.

Patients recruited from METS who developed myocardial injury (median TnI: 0.08ng.ml⁻¹ (interquartile range: 0.05-0.13ng.ml⁻¹)) were clinically similar to patients in whom troponin remained within normal limits (Table 1).

Plasma circulating microRNA expression.

Circulating microRNA expression levels increased for hsa-miR-1-3p (mean fold-change:3.99 (95%CI: 1.95-8.19); $F_{[1,47.5]}=24.16$; $p<0.001$) and hsa-miR-133-3p (fold-change:5.67 (95%CI: 2.94-10.91); $F_{[1,42]}=31.13$; $p<0.001$) after surgery, but were independent of elevated troponin levels after surgery (mixed model level accounting for presence/absence of PMI: $p>0.05$). Expression levels of hsa-miR146a-5p decreased after surgery only in patients with elevated troponin after surgery ($F_{[1,34.5]}=6.43$, $p=0.03$). There was no change in expression for hsa-miR-21-5p after surgery (Figure 2). In patients with troponin elevation after surgery, 91% (20/22) of the samples detected hsa-miR-208b-3p, compared with 50% (12/24) with troponin levels below the 99th centile after surgery (odd ratio (OR):10.00 (95%CI:1.90-52.55); $p<0.01$)). hsa-miR-499a-5p was also detected in a higher proportion of samples from patients with elevated troponin levels after surgery (19/22 vs 13/24; OR:5.36 (95% CI 1.32-24.17); $p<0.05$) surgery. (Supplementary Material; Figure 1)

Pathway analysis

Nine signalling pathways were identified by DIANA in-silica pathway analysis (false-discovery rate <0.01) for microRNA that changed after surgery (Figure 3A). This agnostic analysis approach highlighted the involvement of adrenergic signalling in cardiomyocytes

(hsa04261; $p=0.005$) and arrhythmogenic right ventricular cardiomyopathy (hsa05412; $p=0.006$). All microRNAs that were elevated in serum after surgery ($n=4$) regulated expression of SLC8A1, a gene that controls calcium overload through the NCX1 antiporter membrane protein by removing calcium from cells (Figure 3B). Subunits of protein phosphatase (which regulates cardiac excitability through dephosphorylation of cardiac ion channels), angiotensin receptors and the ATP sarcoplasmic/endoplasmic reticulum calcium pump were also identified as targets of microRNAs that changed after surgery. (Figure 3B)

Cohort 2: microRNA expression levels in extracellular vesicles.

Patient characteristics

Characteristics of the 11 patients from whom samples were obtained 48 hours after surgery are presented in Table 2. The median (IQR) troponin-T values were 19 (17-23) ng.L^{-1} in patients with troponin elevation, compared with patients in whom plasma troponin remained lower than the 99th centile value (median: 6 (5-9) ng.L^{-1} ; $p=0.006$).

Next generation sequencing

A mean of 9.8 million read were obtained for each sample. Mean mapping rate to the genome and microRNA annotation was 62.9%. Mapping to miRbase, with normalisation for differences in the sequences depth within each sample, revealed 345 unique microRNA within all samples where Tags per million (TPM) ≥ 1 and 164 unique microRNAs where TPM ≥ 10 . Thirty-two microRNAs were differentially expressed in patients with troponin elevation after surgery (Figure 4A). After correcting for false discovery rate <0.05 , three microRNAs remained differentially expressed (Figure 4B). The top two biological processes identified through Gene Ontology were associated with cardiac muscle physiology. (Figure 4C; Supplementary material).

Discussion

Our data provide further mechanistic insight into perioperative myocardial injury by quantifying circulating microRNAs from samples obtained serially in patients undergoing non-cardiac surgery. This exploratory study demonstrates that microRNAs are readily detected in serum and extracellular vesicles obtained from patients undergoing non-cardiac surgery. Using technical spike-in quality controls and standardised, reproducible sampling protocols, we report that circulating levels of cardiac-specific microRNAs that increase after ACS^{9, 27} were also elevated after non cardiac surgery. MicroRNA expression levels were independent of troponin levels, suggesting strongly that several microRNA signatures described in the acute coronary syndrome literature reflect a generalised stress/injury response. In support of our circulating microRNA data, agnostic identification of microRNA expression in extracellular vesicles (which, again, was also masked to serial troponin values) revealed pathways from differentially expressed microRNAs that predominantly regulate cardiac muscle contraction. Our findings are consistent with the activation of G protein-coupled receptor signaling mediators, which have an established role through β -arrestins in regulating processing of microRNAs.²⁸ GPCR-mediated stress signalling appears likely to be a dominant factor that contributes to troponin elevation after surgery, since microRNA findings described for myocardial ischaemia/infarction were not recapitulated by our agnostic bioinformatic analyses. Taken together, microRNA data from both plasma extracellular vesicles and serum suggest that a cardiac-stressor phenotype is common amongst patients after non-cardiac surgery, regardless of the development of troponin release and myocardial injury.

Several microRNA have been reported as specific biomarkers for acute coronary syndrome, including miR-499, miR-1, miR-133a/b, and miR-208a/b. In a prospective single-centre study, levels of cardiac miRNAs (miR-1, -208a and -499), miR-21 and miR-146a

increased in 106 patients diagnosed with ACS, even in patients with initially negative high-sensitive troponin or symptom onset <3 h.⁹ The combination of miR-1, miR-499 and miR-21 increased the diagnostic value in all suspected ACS patients, over and above that for hs-troponin T.⁹ However, in contrast to microRNA studies in acute coronary syndrome, we found that troponin elevation after surgery was not related to ACS-specific microRNAs including key players such as miR-1 and miR-133a. In the case of hsa-miR-146a-5p, expression levels were decreased in patients who developed perioperative myocardial injury, in direct contrast to elevated circulating levels reported after myocardial infarction,^{9, 29} MicroRNA-208, a cardiac specific microRNA that regulates cardiac myosin heavy chain expression,³⁰ increases in patients after acute myocardial infarction³¹ but we detected miR-208a in only ~10% patients. Similarly, the low level of detection rates for miR-208b in our study are in contrast to 208b expression levels correlating with troponin levels³² including after acute myocardial infarction²⁹. Although hsa-miR-499a-5p was detected in a higher proportion of patients who developed perioperative myocardial injury, the detection rates for both miR-208b-3p and miR499a-5p we found are consistent with low detection rates reported in the literature^{9, 27} and low constitutive levels in plasma/serum³³.

Our two independent studies analysing microRNA derived from separate sources (serum, extracellular vesicles) suggested common mechanistic targets. Agnostic bioinformatic analyses highlighted microRNA changes in both serum and extracellular vesicles that converge on established gene transcription targets that regulate cardiomyocyte cell calcium homeostasis,³⁴ predominantly involving the sodium-calcium exchanger (NCX1) which is encoded by the SLC8A1 gene.³⁵ Calcium, which enters cardiac myocytes through voltage-dependent Ca(2+) channels during excitation, is extruded from myocytes primarily by NCX1.²⁸ Ischemia/reperfusion reverses the sodium/calcium exchange mechanism, leading to an increase in intracellular calcium concentration, mitochondrial dysfunction and

cardiomyocyte death. However, sustained stress also inhibits NCX1 activity, an effect that requires corticosteroid release in concert with adrenergic activation.³⁶

Reversible protein phosphorylation is essential for excitation-contraction coupling, Ca²⁺ handling, cell metabolism, myofilament regulation, and cell-cell communication.³⁷ ~90% of dephosphorylation events are catalysed by just three phosphatases: PP1, PP2A and PP2B (calcineurin), all of which are regulated by microRNA we identified as changing after surgery. We identified multiple potential PP2A regulatory subunits potentially related to microRNA changes after surgery, which likely reflects the diversity of expression between cardiac cell types, subcellular domains, and disease phenotypes.³⁷ Cardiac myosin binding protein-C (cMyBP-C) and the inhibitory subunit of troponin TnI are also dephosphorylated by both PP1 and PP2A. Targeting of PP2A to TnI is dependent upon the PP2A regulatory subunit B56 α , which is lost following β -adrenergic stimulation. Aberrant regulation of PP2A signaling is a dominant feature in experimental sympathetic-mediated tachycardia and generation of reactive oxygen species.

In the universal presence of a stressor phenotype after surgery, elevations in plasma troponin suggest that loss of cardioprotective mechanisms promote myocardial injury (Figure 4D). An aberrant inflammatory response, as indicated by the decline in expression levels of the anti-inflammatory microRNA hsa-miR-146a-5p, is a plausible mechanism. By inhibiting expression of IRAK1, TRAF6 and NF κ B, hsa-miR-146a-5p suppresses the production of pro-inflammatory cytokines³⁸ which promote myocardial injury.³⁹ Since inflammation is strongly associated with the risk of developing perioperative myocardial injury,³ reduced expression of hsa-miR-146a-5p indicates that dysregulation of inflammation after surgery may contribute to myocardial injury. Furthermore, loss of cardioprotective vagal tone,⁴⁰ which occurs rapidly in many patients during non-cardiac surgery,¹³ is associated with troponin elevation after non-cardiac surgery. Experimental preservation of vagal activity after

myocardial ischaemia maintains normal calcium handling by restoring the protein and mRNA levels of sarcoplasmic reticulum Ca^{2+} ATPase (SERCA2a), NCX1 and phospholamban.⁴¹ The main strength of our study was investigating two separate populations in which we could obtain samples using optimised protocols that enabled microRNA detection in serum and plasma extracellular vesicles to address our overarching hypothesis. Moreover, we compared serial changes in microRNA masked to troponin levels before and after surgery. Reference microRNA were used for normalisation of Cq values. For microRNA that were detected in all samples, the Cq values were consistent with values reported in the literature.²⁹ In fact, the detection threshold in clinical studies using the same microRNA isolated from serum have used much higher threshold i.e Cq <50.²⁷ The utilisation of the spike-in microRNA at isolation, reverse transcription and PCR stage of the experiments allowed for identification of outliers and minimised technical variation within the experiments. A further strength of this work is that the amplification efficiencies are reported in keeping with MIQE guidelines. The low efficiency values for hsa-miR-208b-3p and hsa-miR499a-5p are consistent with reported low detection rates for both.⁴² Our limited targeting of circulating serum microRNAs that are established genomic biomarkers for acute coronary syndrome and myocardial infarction clearly cannot exclude other novel species that may be involved in perioperative myocardial injury. However, the purpose of this initial exploratory study was to investigate whether established ischaemic and/or thrombotic microRNA signatures are present after troponin elevation in non-cardiac surgery.

In summary, expression levels of circulating microRNA that are elevated in acute coronary syndromes also increase after non-cardiac surgery, but this pattern does not appear to be specific for patients with perioperative myocardial injury (as defined by high-sensitivity troponin). MicroRNA changes after non-cardiac surgery appear to occur as a feature of generalised cardiac stress, suggesting that myocardial injury is promoted by deficient

cardioprotective mechanisms that prevent troponin release from otherwise injured cardiomyocytes.

Author Contributions:

Study design: GLA, SMM.

Study conduct: SMM, TEFA, AGDA, AR, GM, RCMS, DB, BHC, DNW, RMP, GLA

Experiments: SMM, AGDA, GLA

Data analysis: SMM, GLA

Drafting/revising manuscript: GLA, SMM.

Critical review: all authors.

Figure 1: METS study 1 flow diagram, illustrating patient/sample selection.




Figure 2: Heatmaps showing relative expression levels (Fold change) of detectable serum microRNA before and after non-cardiac surgery, in relation to the development of myocardial injury.

A-D: Heatmap showing relative serum expression levels for each matched sample using the relative Cq method. MicroRNA Cq values were normalised to the geometric mean of the reference microRNA Cq values to give ΔCq values. The ΔCq values were converted to a fold change (FC) by applying the formula of $2^{-\Delta Cq}$. Bars below each microRNA heatmap indicate range of fold-change expression (\log_2 scaled). Black bars denote sample that failed strict quality control threshold. **E-H:** Relative change in MicroRNA expression levels after surgery. Bars are mean fold change with 95% confidence intervals. P-values refer to comparison; before surgery vs after surgery (analysed by mixed-model repeated measures and Bonferroni test); * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. PMI: perioperative myocardial injury (defined as troponin I (TnI) > 99 th centile (> 0.04 ng.ml¹).




Figure 3: Bioinformatic analysis identifying pathways and genes regulated by serum microRNAs that change after non-cardiac surgery.

A. Signalling pathways (false-discovery rate threshold p value <0.01), as derived from DIANA mir-Path v3.0, which bioinformatically links microRNA with their regulatory roles in biological and signalling pathways. Cardiac-specific pathways are highlighted in red.

B. Shared genes regulated by serum microRNA identified as changing after non-cardiac surgery. The four microRNAs identified as changing after surgery regulate mRNA expression of SLC8A1 (NCX1 sodium-calcium exchanger) and subunits of the protein phosphatase enzyme.




Figure 4: Next generation sequencing of microRNAs detected in extracellular vesicles.

A. Heat map showing all differentially expressed microRNA ($P < 0.05$), comparing patients with PMI ($\text{hsTnT} > 14 \text{ngL}^{-1}$) versus no troponin elevation. Values are Trimmed mean of M values. (Z score transformation; red indicates higher expression levels).

B. Volcano plot of microRNAs identified in all samples. Green dots denote differentially expressed microRNA with adjusted p-value (FDR; false discovery rate) < 0.05 . Orange dots denote differentially expressed microRNA with p-value < 0.05 and red dots denote microRNA that were not differentially expressed.

C. GO terms that were significantly enriched among the differentially expressed microRNA, comparing patients with PMI ($\text{hsTnT} > 14 \text{ngL}^{-1}$) versus no troponin elevation.

D. Refined hypothesis of mechanisms contributing to perioperative myocardial injury, summarising chief microRNA findings and their potential roles in cardioprotection. Blue coloured microRNA species have been associated with cardioprotection, while red coloured microRNAs promote cardiac injury in the setting of ischaemia/reperfusion injury. Trop I- troponin I; Trop C- troponin C; Trop T- troponin T. Adrenergic stress is a common feature of the perioperative period, leading to the release of microRNA from cardiac cells, which may be cardiomyocytes, fibroblasts or other cell types. In individuals at highest risk of elevated troponin after surgery (e.g. elderly, patients with cardiac failure, diabetes mellitus, renal disease), pre-existing (preoperative), or acquired, loss of cardioprotective signalling mechanisms promotes the likelihood of calcium overload from adrenergic stress, resulting in mitochondrial dysfunction, bioenergetic compromise and myocardial injury manifest clinically by the measurement (at low levels) of troponin T in plasma/serum.




Table 1: Patient characteristics for METS study cohort.

Data is presented as mean with standard deviations (SD) for parametric data and as median (25th-75th interquartile range) for non-parametric data. Frequencies are presented with percentages (%). Age is rounded to the nearest year. Perioperative myocardial injury (PMI) defined was defined as troponin I (TnI) >99th centile (>0.04 ng.ml⁻¹) after surgery. eGFR: estimated glomerular filtration rate. RCRI: Revised cardiac risk index score. ACE-I: Angiotensin converting enzyme inhibitor. ARB: angiotensin receptor blocker. Other units as indicated. #Previous diagnosis of asthma, reactive airways disease, chronic obstructive lung disease, chronic bronchitis, or emphysema. *Indication for surgery was for treatment of cancer. Statistical analysis using paired-sample t-test or Wilcoxon-Signed rank test for continuous data and Chi- Squared test for categorical data.

| | Whole cohort n=48 | No PMI n=24 | PMI n=24 | <i>p-value</i> |
|---|----------------------|----------------|------------------|----------------|
| Troponin level ng ml ⁻¹ | | ≤0.04 | 0.08 (0.05-0.13) | <0.001 |
| Clinical Characteristics | | | | |
| Age (yr) | 67 (61-75) | 67 (60-74) | 66 (61-76) | 0.154 |
| Male sex (n;%) | 22 (45.8%) | 11 (45.8%) | 11 (45.8%) | 1.000 |
| Body Mass Index (kg m ⁻²) | 27 (5) | 27(5) | 27 (5) | 0.900 |
| Before surgery eGFR (ml.min..1.73m ²) | 87 (76-96) | 84 (72-94) | 90 (79-103) | 0.192 |
| Haemoglobin (g dl ⁻¹) | 130 (22) | 128 (16) | 131 (26) | 0.520 |
| Co-morbidities (n; %) | | | | |
| RCRI ≥2 | 4 (8.3%) | 2 (8.3%) | 2 (8.3%) | 1.000 |
| Coronary artery disease | 5 (10.4%) | 3 (12.5%) | 2 (8.3%) | 0.637 |
| Congestive heart failure | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - |
| Cerebrovascular disease | 1 (2.1%) | 1 (4.2%) | 0 (0.0%) | 0.312 |
| Diabetes Mellitus | 10 (20.8%) | 5(20.8%) | 5 (20.8%) | 1.000 |
| Peripheral vascular disease | 1 (2.1%) | 0 (0.0%) | 1 (4.2%) | 0.312 |
| Hypertension | 24 (50.0%) | 11(45.8%) | 13 (54.2%) | 0.564 |
| Obstructive lung disease [#] | 5 (10.4%) | 3 (12.5%) | 2 (8.3%) | 0.636 |
| Significant malignancy [*] | 34 (70.8%) | 18 (75.0%) | 16 (66.7%) | 0.524 |
| Preoperative medications | | | | |
| Beta blocker | 6 (12.5%) | 4 (16.7%) | 2 (8.3%) | 0.383 |
| Calcium channel blocker | 5 (10.4%) | 3 (12.5) | 2 (8.3%) | 0.637 |
| ARB/ACE-I | 19 (39.5%) | 8 (33.3%) | 11 (45.8%) | 0.376 |
| Aspirin | 8 (16.7%) | 4 (16.7%) | 4 (16.7%) | 1.000 |
| Surgical Procedure type (n; %) | | | | |
| Intraperitoneal or retroperitoneal | 30 (62.5%) | 17 (70.8%) | 13 (54.2%) | 0.223 |
| Urology or gynaecological | 15 (31.3%) | 6 (25.0%) | 9 (37.5%) | 0.350 |
| Orthopaedic | 3 (6.2%) | 1 (4.2%) | 2 (8.3%) | 0.551 |
| Anaesthesia Type (n; %) | | | | |
| General Anaesthesia alone | 24 (50.0%) | 13(54.2%) | 11 (45.8%) | 0.564 |
| General + regional anaesthesia | 24 (50.0%) | 11 (45.8%) | 13 (54.2%) | 0.564 |

Table 2: Patient characteristics of X-MINS study cohort

Data is presented as mean with standard deviations (SD) for parametric data and as median (25th-75th interquartile range) for non-parametric data. Frequencies are presented with percentages (%). Age is rounded to the nearest year. Perioperative myocardial injury was defined as plasma high sensitivity Troponin T Assay $\geq 99^{\text{th}}$ centile ($\geq 15 \text{ ng.L}^{-1}$) within 2 days of surgery. eGFR: estimated glomerular filtration rate. RCRI: Revised cardiac risk index score. ACE-I: Angiotensin converting enzyme inhibitor. ARB: angiotensin receptor blocker. Other units as indicated. [#]Previous diagnosis of asthma, reactive airways disease, chronic obstructive lung disease, chronic bronchitis, or emphysema. *Indication for surgery was for treatment of cancer.

| | Whole cohort | No PMI n=5 | PMI n = 6 |
|---|--------------|---------------|--------------|
| Troponin level ng L ⁻¹ | | 6(5-9) | 19 (17-23) |
| Clinical Characteristics | | | |
| Age (yr) | 70 (64-76) | 68(62-71) | 74 (68-81) |
| Male sex (n;%) | 3 (27.3%) | 1 (20%) | 2 (33.3%) |
| Body Mass Index (kg m ⁻²) | 31 (8) | 30 (7) | 32 (9) |
| Before surgery eGFR (ml.min..1.73m ²) | 83(65-90) | 77 (66-89) | 87(49-90) |
| Haemoglobin (g L ⁻¹) | 12.5 (2.1) | 12.7 (1.7) | 12.4 (2.5) |
| Co-morbidities (n; %) | | | |
| RCRI ≥ 2 | 2 (18.2%) | 1 (20%) | 1 (16.7%) |
| Coronary artery disease | 0 (0.0%) | 0 (0%) | 0 (0%) |
| Congestive heart failure | 0 (0.0%) | 0 (0%) | 0 (0%) |
| Cerebral vascular disease | 2 (18.2%) | 1 (20%) | 1 (16.7%) |
| Diabetes mellitus | 2 (18.2%) | 0 (0%) | 2 (33.3%) |
| Peripheral vascular disease | 1 (9.1%) | 1 (20%) | 0 (0%) |
| Hypertension | 6 (54.5%) | 3 (60%) | 3 (50%) |
| Obstructive lung disease [#] | 3 (27.3%) | 1 (20%) | 2 (33.3%) |
| Significant malignancy [*] | 7 (46.6%) | 2 (40%) | 5 (83.3%) |
| Preoperative medications | | | |
| Beta blocker | 2 (18.2%) | 0 (%) | 2 (33.3%) |
| Calcium channel blocker | 1 (9.1%) | 0 (0%) | 1 (16.7%) |
| ARB/ACE-I | 4 (36.4%) | 2 (40%) | 2 (33.3%) |
| Aspirin | 2 (18.2%) | 2 (40%) | 0 (0%) |
| Type of surgery (n; %) | | | |
| Intraperitoneal or retroperitoneal | 2 (18.2%) | 1 (20%) | 1 (16.7%) |
| Urology/gynaecological | 5 (45.4%) | 2 (40%) | 3 (50%) |
| Orthopaedic | 4 (36.4%) | 2 (40%) | 2 (33.3%) |
| Type of anaesthesia (n; %) | | | |
| General Anaesthesia alone | 4 (36.4%) | 2 (40%) | 2 (33.3%) |
| General + regional anaesthesia | 7 (63.6%) | 3 (60%) | 4 (66.7%) |

Declarations

GLA is an Editor for Intensive Care Medicine Experimental and British Journal of Anaesthesia. GLA has undertaken consultancy work for GlaxoSmithKline; TEFA is a member of the associate editorial board of British Journal of Anaesthesia; there are no other relationships or activities that could appear to have influenced the submitted work.

Sources of funding

GLA is supported by British Journal of Anaesthesia/Royal College of Anaesthetists basic science Career Development award, British Oxygen Company research chair grant in anaesthesia from the Royal College of Anaesthetists and British Heart Foundation Programme Grant (RG/14/4/30736). New Investigator Award from the Canadian Institutes of Health Research to DNW; Endowed Chair in Translational Anesthesiology Research at St Michael's Hospital and University of Toronto to DNW; Merit Awards from the Department of Anesthesia at the University of Toronto to DNW, CDM, and BHC; Medical Research Council (UK) Clinical Research Training Fellowship to TEFA. The METS study was supported by grants from the Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, Ontario Ministry of Health and Long-Term Care, Ontario Ministry of Research and Innovation, United Kingdom (UK) National Institute of Academic Anaesthesia, UK Clinical Research Collaboration, Australian and New Zealand College of Anaesthetists, and Monash University (Melbourne, Victoria, Australia).

References

- 1 Botto F, Alonso-Coello P, Chan MT, et al. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. *Anesthesiology* 2014; **120**: 564-78
- 2 Ackland GL, Abbott TEF, Jones TF, Pearse RM, Investigators. V-U. Early elevation in plasma high-sensitivity troponin T and noncardiac morbidity after elective non-cardiac surgery: prospective multi-centre observational cohort study. *Br J Anaesth* 2020; **BJA-2019-01697-PM101**
- 3 Ackland GL, Abbott TEF, Cain D, et al. Preoperative systemic inflammation and perioperative myocardial injury: prospective observational multicentre cohort study of patients undergoing non-cardiac surgery. *British journal of anaesthesia* 2019; **122**: 180-7
- 4 Navickas R, Gal D, Laucevicius A, Taparauskaite A, Zdanyte M, Holvoet P. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. *Cardiovasc Res* 2016; **111**: 322-37
- 5 Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. *Nat Rev Mol Cell Biol* 2019; **20**: 5-20
- 6 Chistiakov DA, Orekhov AN, Bobryshev YV. Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction). *J Mol Cell Cardiol* 2016; **94**: 107-21
- 7 Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* 2007; **9**: 654-9
- 8 Kaur A, Mackin ST, Schlosser K, et al. Systematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease. *Cardiovascular Research* 2019
- 9 Oerlemans MI, Mosterd A, Dekker MS, et al. Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. *EMBO Mol Med* 2012; **4**: 1176-85
- 10 van Rooij E. The Art of MicroRNA Research. *Circulation Research* 2011; **108**: 219-34
- 11 Creemers EE, Tijssen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? *Circ Res* 2012; **110**: 483-95
- 12 Wijeyesundera DN, Pearse RM, Shulman MA, et al. Assessment of functional capacity before major non-cardiac surgery: an international, prospective cohort study. *Lancet* 2018; **391**: 2631-40
- 13 May SM, Reyes A, Martir G, et al. Acquired loss of cardiac vagal activity is associated with myocardial injury in patients undergoing noncardiac surgery: prospective observational mechanistic cohort study. *Br J Anaesth* 2019; **123**: 758-67
- 14 Cheng C, Wang Q, You W, Chen M, Xia J. MiRNAs as biomarkers of myocardial infarction: a meta-analysis. *PLoS One* 2014; **9**: e88566
- 15 Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. *Nucleic Acids Res* 2019; **47**: D155-D62
- 16 Blondal T, Jensby Nielsen S, Baker A, et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. *Methods* 2013; **59**: S1-6
- 17 Ruijter JM, Ramakers C, Hoogaars WM, et al. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. *Nucleic Acids Res* 2009; **37**: e45

- 18 Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. *RNA* 2008; **14**: 844-52
- 19 Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. *Cancer Res* 2004; **64**: 5245-50
- 20 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001; **25**: 402-8
- 21 Vlachos IS, Zagganas K, Paraskevopoulou MD, et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. *Nucleic Acids Res* 2015; **43**: W460-6
- 22 Langmead B, Wilks C, Antonescu V, Charles R. Scaling read aligners to hundreds of threads on general-purpose processors. *Bioinformatics* 2018; **35**: 421-32
- 23 Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 2010; **26**: 139-40
- 24 Alexa A, Rahnenfuhrer J, Lengauer T. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. *Bioinformatics* 2006; **22**: 1600-7
- 25 Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets--update. *Nucleic Acids Res* 2013; **41**: D991-5
- 26 Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* 2011; **12**: 77
- 27 Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. *J Mol Cell Cardiol* 2011; **51**: 872-5
- 28 Xiao K, McClatchy DB, Shukla AK, et al. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. *Proc Natl Acad Sci USA* 2007; **104**: 12011-6
- 29 Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. *Eur Heart J* 2010; **31**: 659-66
- 30 van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. *Science* 2007; **316**: 575-9
- 31 Xiao J, Shen B, Li J, et al. Serum microRNA-499 and microRNA-208a as biomarkers of acute myocardial infarction. *Int J Clin Exp Med* 2014; **7**: 136-41
- 32 Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. *Circ Cardiovasc Genet* 2010; **3**: 499-506
- 33 Adachi T, Nakanishi M, Otsuka Y, et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. *Clin Chem* 2010; **56**: 1183-5
- 34 Harada M, Luo X, Murohara T, Yang B, Dobrev D, Nattel S. MicroRNA regulation and cardiac calcium signaling: role in cardiac disease and therapeutic potential. *Circ Res* 2014; **114**: 689-705
- 35 Shattock MJ, Ottolia M, Bers DM, et al. Na⁺/Ca²⁺ exchange and Na⁺/K⁺-ATPase in the heart. *J Physiol* 2015; **593**: 1361-82
- 36 Hudecova S, Kubovcakova L, Kvetnansky R, et al. Modulation of expression of Na⁺/Ca²⁺ exchanger in heart of rat and mouse under stress. *Acta Physiol (Oxf)* 2007; **190**: 127-36
- 37 Lubbers ER, Mohler PJ. Roles and regulation of protein phosphatase 2A (PP2A) in the heart. *J Mol Cell Cardiol* 2016; **101**: 127-33
- 38 Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. *Proc Natl Acad Sci U S A* 2006; **103**: 12481-6

- 39 Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. *Nat Rev Cardiol* 2014; **11**: 255-65
- 40 Abbott TEF, Pearse RM, Cuthbertson BH, Wijeyesundera DN, Ackland GL, investigators Ms. Cardiac vagal dysfunction and myocardial injury after non-cardiac surgery: a planned secondary analysis of the measurement of Exercise Tolerance before surgery study. *Br J Anaesth* 2019; **122**: 188-97
- 41 Zhang Y, Chen A, Song L, et al. Low-Level Vagus Nerve Stimulation Reverses Cardiac Dysfunction and Subcellular Calcium Handling in Rats With Post-Myocardial Infarction Heart Failure. *Int Heart J* 2016; **57**: 350-5
- 42 Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin Chem* 2009; **55**: 611-22